Your browser doesn't support javascript.
loading
Interferon induction, evasion, and paradoxical roles during SARS-CoV-2 infection.
Chiale, Carolina; Greene, Trever T; Zuniga, Elina I.
Afiliação
  • Chiale C; Division of Biological Sciences, University of California San Diego, La Jolla, California, USA.
  • Greene TT; Division of Biological Sciences, University of California San Diego, La Jolla, California, USA.
  • Zuniga EI; Division of Biological Sciences, University of California San Diego, La Jolla, California, USA.
Immunol Rev ; 309(1): 12-24, 2022 08.
Article em En | MEDLINE | ID: mdl-35775361
ABSTRACT
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the causative agent of coronavirus disease 2019 (COVID-19), has caused millions of deaths in the past two years. Although initially little was understood about this virus, recent research has significantly advanced and landed interferons (IFNs) in the spotlight. While Type I and III IFN have long been known as central to antiviral immunity, in the case of COVID-19 their role was initially controversial. However, the protective function of IFN is now well supported by the identification of human deficiencies in IFN responses as a predictor of disease severity. Here, we will review the cell types and pathways that lead to IFN production as well as the importance of IFN timing and location for disease outcome. We will further discuss the mechanisms that SARS-CoV-2 uses to evade IFN responses, and the current efforts to implement IFNs as therapeutics in the treatment of COVID-19. It is essential to understand the relationships between SARS-CoV-2 and IFN to better inform treatments that exploit IFN functions to alleviate COVID-19.
Assuntos
Palavras-chave

Texto completo: 1 Bases de dados: MEDLINE Assunto principal: Interferon Tipo I / COVID-19 Tipo de estudo: Prognostic_studies Limite: Humans Idioma: En Revista: Immunol Rev Ano de publicação: 2022 Tipo de documento: Article País de afiliação: Estados Unidos

Texto completo: 1 Bases de dados: MEDLINE Assunto principal: Interferon Tipo I / COVID-19 Tipo de estudo: Prognostic_studies Limite: Humans Idioma: En Revista: Immunol Rev Ano de publicação: 2022 Tipo de documento: Article País de afiliação: Estados Unidos